Skip to main content

Coeur Mining, Inc. Announces Expiration of Tender Offer for its Outstanding 5.875% Senior Notes Due 2024

CHICAGO -- Coeur Mining, Inc. (NYSE: CDE) (the “Company”) announced today that its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its 5.875% senior notes due 2024 (the “2024 Notes”) expired at 5:00 p.m., New York City time, on February 26, 2021 (the “Expiration Time”). As of the Expiration Time, $102,817,000 aggregate principal amount of the 2024 Notes (or 44.70% of the total aggregate principal amount of the 2024 Notes outstanding) were validly tendered, which excludes $396,000 aggregate principal amount of the 2024 Notes (or 0.17% of the total aggregate principal amount of the 2024 Notes outstanding) that remain subject to the guaranteed delivery procedures set forth in the Company’s Offer to Purchase, dated February 22, 2021 (the “Offer to Purchase”). The Company expects to accept for payment all such 2024 Notes validly tendered and not validly withdrawn in the Tender Offer and expects to make payment for the 2024 Notes on March 1, 2021, or, in the case of 2024 Notes validly tendered and accepted for purchase pursuant to the guaranteed delivery procedures, on March 3, 2021, in each case, subject to the closing of the Company’s previously announced debt financing transaction and the satisfaction or waiver by the Company of the other conditions listed in the Offer to Purchase. Following the consummation of the Tender Offer, the Company intends to redeem any 2024 Notes not validly tendered and purchased in the Tender Offer, at a redemption price equal to 102.938% of the principal amount redeemed, plus any accrued and unpaid interest to the redemption date. Read More

from Financial Post https://ift.tt/2O5WFCo
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more